These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis. Ho-Tin-Noé B; Rojas G; Vranckx R; Lijnen HR; Anglés-Cano E FEBS J; 2005 Jul; 272(13):3387-400. PubMed ID: 15978044 [TBL] [Abstract][Full Text] [Related]
5. Annexin II and regulation of cell surface fibrinolysis. Hajjar KA; Acharya SS Ann N Y Acad Sci; 2000 May; 902():265-71. PubMed ID: 10865846 [TBL] [Abstract][Full Text] [Related]
6. Overview on fibrinolysis: plasminogen activation pathways on fibrin and cell surfaces. Anglés-Cano E Chem Phys Lipids; 1994 Jan; 67-68():353-62. PubMed ID: 8187235 [TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site. Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375 [TBL] [Abstract][Full Text] [Related]
10. On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity. Bydoun M; Waisman DM Future Oncol; 2014 Dec; 10(15):2469-79. PubMed ID: 25525855 [TBL] [Abstract][Full Text] [Related]
11. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator. Anglés-Cano E; Hervio L; Rouy D; Fournier C; Chapman JM; Laplaud M; Koschinsky ML Chem Phys Lipids; 1994 Jan; 67-68():369-80. PubMed ID: 8187237 [TBL] [Abstract][Full Text] [Related]
12. Antifibrinolytic effect of single apo(a) kringle domains: relationship to fibrinogen binding. Rahman MN; Petrounevitch V; Jia Z; Koschinsky ML Protein Eng; 2001 Jun; 14(6):427-38. PubMed ID: 11477223 [TBL] [Abstract][Full Text] [Related]
13. Factors that control extravascular fibrinolysis. Chung SI; Lee SY; Uchino R; Carmassi F Semin Thromb Hemost; 1996; 22(6):479-88. PubMed ID: 9122712 [TBL] [Abstract][Full Text] [Related]
14. Annexin II: a plasminogen-plasminogen activator co-receptor. Kim J; Hajjar KA Front Biosci; 2002 Feb; 7():d341-8. PubMed ID: 11815288 [TBL] [Abstract][Full Text] [Related]
15. A mediator of cell surface-specific plasmin generation. Brownstein C; Falcone DJ; Jacovina A; Hajjar KA Ann N Y Acad Sci; 2001 Dec; 947():143-55; discussion 155-6. PubMed ID: 11795262 [TBL] [Abstract][Full Text] [Related]
16. The macrophage and fibrinolysis. Loscalzo J Semin Thromb Hemost; 1996; 22(6):503-6. PubMed ID: 9122715 [TBL] [Abstract][Full Text] [Related]
17. Is diabetic hypercoagulability an acquired annexinopathy? Glycation of annexin II as a putative mechanism for impaired fibrinolysis in diabetic patients. Gugliucci A; Ghitescu L Med Hypotheses; 2002 Sep; 59(3):247-51. PubMed ID: 12208147 [TBL] [Abstract][Full Text] [Related]
18. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. Ling Q; Jacovina AT; Deora A; Febbraio M; Simantov R; Silverstein RL; Hempstead B; Mark WH; Hajjar KA J Clin Invest; 2004 Jan; 113(1):38-48. PubMed ID: 14702107 [TBL] [Abstract][Full Text] [Related]
19. [Platelets, coagulation, and fibrinolysis in atherosclerosis formation]. Ishii H; Yoshida M Nihon Rinsho; 2011 Jan; 69(1):50-4. PubMed ID: 21226260 [TBL] [Abstract][Full Text] [Related]
20. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Sharma MC; Sharma M Curr Pharm Des; 2007; 13(35):3568-75. PubMed ID: 18220793 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]